The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Current and future therapeutic approaches for osteosarcoma
Abstract
INTRODUCTION: Current treatment of osteosarcoma includes surgical resection of all gross disease in conjunction with systemic chemotherapy to control micro-metastatic disease. This yields a 5-year event free survival (EFS) of approximately 70% for patients with localized osteosarcoma while patients with metastatic or recurrent disease fare poorly with overall survival rates of less than 20%. Areas covered: This review outlines the current and future approach towards the treatment of osteosarcoma. A literature search was performed utilizing PubMed. Several recent clinical trials are reviewed in detail, as is innovative research evaluating novel agents and surgical techniques which hold promise. Expert commentary: The outcome for patients with osteosarcoma has not changed in several decades. This plateau in survival rates highlights the need for a novel approach towards research. There remains a great deal of interest in utilizing the very high risk population of recurrent osteosarcoma patients to rapidly and sequentially evaluate novel agents to determine if any of these agents hold promise. Several phase II studies are ongoing or in development that offer hope based on intriguing preclinical data. Furthermore, initiatives in obtaining specimens to further explore the genetic and immunological profile behind osteosarcoma will be essential towards identifying novel pathways and targets to exploit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
US Department of Health and Human Services; National Cancer Institute (1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,947
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,567
Self-citationOsteosarcoma treatment – Where do we stand? A state of the art review
Luetke, A., Meyers, P. A., Lewis, I., & Juergens, H. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.006 · Cited by 1,234
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e · Cited by 1,090
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24320 · Cited by 791
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
Cited by
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Gazouli, I., Kyriazoglou, A., Kotsantis, I., Anastasiou, M., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Kontogeorgakos, V., et al. (2021) · Cancers · doi:10.3390/cancers13081757 · Cited by 63
Duan, X. L., Guo, J. P., Li, F., Xiu, C., & Wang, H. (2020) · Future Oncology · doi:10.2217/fon-2019-0725 · Cited by 30
A novel small-molecule near-infrared II fluorescence probe for orthotopic osteosarcoma imaging
Lin, J., Li, Q., Zeng, X., Chen, Z., Ding, Q., Li, Y., Zhou, H., Meng, X., Chen, D., Deng, Z., et al. (2020) · Science China Chemistry · doi:10.1007/s11426-019-9685-6 · Cited by 29
T cell exhaustion drives osteosarcoma pathogenesis
Sun, C.-Y., Zhang, Z., Tao, L., Xu, F.-F., Li, H.-Y., Zhang, H.-Y., & Liu, W. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3928 · Cited by 29
HIGUCHI, T., IGARASHI, K., YAMAMOTO, N., HAYASHI, K., KIMURA, H., MIWA, S., BOUVET, M., TSUCHIYA, H., & HOFFMAN, R. M. (2021) · Anticancer Research · doi:10.21873/anticanres.15406 · Cited by 25
Metadata
- Authors
- Harrison, D. J., Geller, D. S., Gill, J. D., Lewis, V. O., & Gorlick, R.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-12-14
- Volume
- 18
- Issue
- 1
- Pages
- 39-50
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2775185528
- Cited by
- 689
- References
- 92
- FWCI
- 41.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and future therapeutic approaches for osteosarcoma. https://app.cochat.ai/papers/10.1080/14737140.2018.1413939
- The paper
- Harrison, D. J., Geller, D. S., Gill, J. D., Lewis, V. O., & Gorlick, R. (2018). Current and future therapeutic approaches for osteosarcoma. Expert Review of Anticancer Therapy. https://doi.org/10.1080/14737140.2018.1413939
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
